

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-4. (canceled)

5. (currently amended) The ~~drug-kit for cancer therapy~~ of claim 24, wherein the adenovirus of (a) ~~the oncolytic virus~~ has a promoter selected from the group consisting of 1A1.3B promoter, midkine promoter,  $\beta$ -HCG promoter, SCCA1 promoter, cox-2 promoter, PSA promoter and a tumor specific promoter according to the type of cancer to be treated.

6. (currently amended) The ~~drug-kit for cancer therapy~~ of claim 24, further comprising: (i) atelocollagen.

7. (withdrawn - currently amended) The ~~drug-kit for cancer therapy~~ of claim 24, further comprising: (i) a GM-CSF expression virus vector, which when grown with the carrier cell, the carrier cell becomes infected with the GM-CSF expression virus vector.

8. (withdrawn - currently amended) The ~~drug-kit for cancer therapy~~ of claim 24, further comprising: at least one composition selected from the group consisting of:

(i) an iron preparation and

(ii) a porphyrin compound.

9. (withdrawn - currently amended) The ~~drug-kit for cancer therapy~~ of claim 24, further comprising: (i) a tumor cell, which is administered to the animal for tumor vaccination.

10. (canceled)

11. (currently amended) The method of cancer ~~gene~~-therapy of claim 25, wherein permitting induction of a cytotoxic T lymphocyte reaction in the subject ~~the period after administering the virus for immunological treatment is~~ conducted within the range of about two weeks to not more than 13 weeks.

12. (currently amended) The method of cancer ~~gene~~-therapy of claim 25, wherein the non-proliferative strain of adenovirus ~~virus for immunological treatment is~~ administered in an amount between about  $10^5$  viral particles and  $10^{11}$  viral particles to a subject patient ~~who is negative for the antibodies to the strain~~ virus, and is administered in an amount between about  $10^2$  viral particles and  $10^7$  viral particles to a subject patient who is positive for ~~the antibodies to the strain~~ virus.

13. (withdrawn - currently amended) The method of cancer ~~gene~~-therapy of claim 25, wherein the ~~oncolytic virus infected carrier cell population of carrier cells~~ infected with the proliferative strain of adenovirus delivers an amount of adenovirus ~~oncolytic virus of~~ between about  $10^9$  viral particles and  $10^{14}$  viral particles to the subject patient.

14. (withdrawn - currently amended) The method of cancer ~~gene~~-therapy of claim 25, wherein the ~~oncolytic virus infected carrier cell population of carrier cells~~ infected with the proliferative strain of adenovirus ~~comprises~~ has an amount of viral particles between about 0.1 viral particles/cell and 2,000 viral particles/cell.

15. (currently amended) The method of cancer ~~gene~~-therapy of claim 25, where the administering of the ~~oncolytic virus infected carrier cell population of carrier cells~~ infected with the proliferative strain of adenovirus is by intratumor injection.

16. (currently amended) The method of cancer ~~gene~~-therapy of claim 25, further comprising: administering atelocollagen with the ~~oncolytic virus infected carrier cell population of carrier cells~~ infected with the proliferative strain of adenovirus in step (c)(d).

17. (withdrawn - currently amended) The method of cancer gene therapy of claim 25, where the population of carrier cells ~~cell in step (c)~~ is grown with the proliferative strain of adenovirus ~~an oncolytic virus~~ and a GM-CSF expression virus vector to produce a population of carrier cells ~~cell~~ infected with the proliferative strain of adenovirus ~~an oncolytic virus~~ and a GM-CSF expression virus vector.

18. (withdrawn - currently amended) The method of cancer gene therapy of claim 25, further comprising administering to the subject at least one composition selected from the group consisting of an iron preparation and a porphyrin compound, with the ~~oncolytic virus infected population of carrier cells~~ cell infected with the proliferative strain of adenovirus in step (c) ~~(d)~~.

19. (withdrawn - currently amended) The method of cancer gene therapy of claim 25, further comprising administering to the subject a tumor cell to produce tumor vaccination, at a time selected from the group consisting of: before, after and concurrent with administering the non-proliferative strain of adenovirus ~~virus in step (a)~~ for immunological treatment.

20-23. (canceled)

24. (currently amended) A drug kit for cancer therapy comprising:

(a) an adenovirus ~~a non-proliferative virus~~ for immunological treatment, which when administered to an animal produces a Cytotoxic T lymphocytes (CTL) reaction within the animal after administering a carrier cell;

(b) a non-proliferative strain of adenovirus ~~the carrier cell, which when grown with an oncolytic virus becomes infected with the oncolytic virus so when the carrier cell is administered to the animal the oncolytic virus acts on a tumor cell within the animal;~~  
and

(c) a carrier cell for providing adenovirus of (a) to an animal, ~~the oncolytic virus, which is the same type of virus as the virus for immunological treatment and which is~~

~~proliferative in the tumor cell; and wherein the carrier cell is a population of selected from the group consisting of (1) A549 cells or a population and (2) mixture of A549 cells and 293 cells.~~

25. (currently amended) A method of cancer ~~gene~~-therapy in a subject, comprising:

(a) administering a non-proliferative strain of an adenovirus to a subject in need of treatment~~virus for immunological treatment to a patient to induce a Cytotoxic T lymphocytes (CTL) reaction within the patient after administering a carrier cell;~~

(b) permitting induction of a cytotoxic T lymphocyte reaction in the subject~~waiting a period after administering the virus for immunological treatment before continuing with the method of cancer gene therapy;~~

(c) ~~after waiting the period, growing a carrier cell with an oncolytic virus to produce an oncolytic virus infected carrier cell, wherein the oncolytic virus is the same type of virus as the virus for immunological treatment; and~~

(c)(d) administering a population of carrier cells to the subject, wherein the carrier cells are infected with a proliferative strain of an adenovirus, and administering the oncolytic virus infected carrier cell, at least one time, to the patient to make the oncolytic virus act on a tumor cell within the patient, and wherein the oncolytic virus is proliferative in the tumor cell; and wherein the population of carrier cells is ~~selected from the group consisting of (1) a population of A549 cells or a population of and (2) mixture of A549 cells and 293 cells.~~